Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 39 - General protective or antinoxious agents
Patents for A61P 39 - General protective or antinoxious agents (19,019)
11/2003
11/13/2003US20030211077 Stimulanting hematopoiesis
11/13/2003CA2484258A1 Soya cell strains with high isoflavone content
11/13/2003CA2483857A1 Use of dimesna for mitigating taxane induced neurotoxicity
11/12/2003EP1360173A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/12/2003EP1359929A1 Phytotherapeutic composition for eliminating heavy metals
11/12/2003EP1359924A1 Endotoxin binding by lactic acid bacteria and bifidobacteria
11/12/2003EP1359923A1 Use of selenite or preparations containing selenite for treating wounds
11/12/2003EP1359897A2 Cosmetic composition and method for reducing or preventing wrinkling
11/12/2003EP1304114A9 Adsorbent for endocrine disruptors and foods and drinks containing the same
11/12/2003EP1210105B1 High density lipoprotein against organ dysfunction following haemorrhagic shock
11/12/2003CN1455770A (2-azabicyclo [2,2,1] hept-7-yl] methanol derivatives as nicotinic acetylcholine receptor agonisis
11/12/2003CN1454604A Medicine for curing hydrophobia during morbidity
11/11/2003US6646009 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/11/2003US6645531 Halting, diminishing, or inhibiting the growth of at least one of a bacterium, a fungus; a parasitic microbe, and a virus, which method comprises administering at least one electron active compound
11/11/2003US6645501 Anti-pathogen system and methods of use thereof
11/06/2003WO2003091266A2 Protein stabilisation using chaperone proteins
11/06/2003WO2003091247A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/05/2003EP1359215A1 Soya cell strains with high isoflavone content
11/05/2003EP1358886A1 Excretion accelerator for accumulative chlorine compound
11/05/2003EP1357895A2 Vaccine composition and stabilisation method
11/05/2003EP1357811A1 Composition and method for smoke detoxification
11/05/2003CN1454213A Variants of allergenic proteins of the Group2 of dermatophagoides
11/05/2003CN1453275A Novel indodyl oxazole compound and its prepn. and application
11/05/2003CN1453027A Medicine prepn for preventing and retarding side effect of chemotherapy and its prepn process
11/05/2003CN1452973A Orally taken antioxidant and antilipemic medicine
11/05/2003CN1126552C Marine biological selenium products and preparing process thereof
11/05/2003CN1126546C Reduction of infarction region using citicoline
11/04/2003US6642235 Administering a therapeutically effective amount of a formulation comprising compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of 5000; for selectively inhibiting reuptake of norepinephrine
11/04/2003US6641824 Skin treatment using a new retinoid
10/2003
10/30/2003WO2002097030A3 Peptides derived from neural thread proteins and their medical use
10/30/2003WO2002034783A3 Transmembrane proteins
10/30/2003WO2002032447A3 Cell damage inhibitor
10/30/2003US20030203973 Administering triethylenetetramine to lower copper value of myocardium; for treatment of diabetes
10/30/2003US20030203960 Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
10/30/2003US20030203955 Administering to a patient suffering from an immune cell mediated diseases a therapeutic amount of biheterocyclic compound containing sulfone group or substituted suflone
10/30/2003US20030203954 Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
10/30/2003US20030203874 Revitalization formulation
10/30/2003US20030203057 A mixture of isoflavones or isoflavone glycosides, pungent, bitter and sour substances and/or scymnol and scymnol esters; secretion of biogenic monoamines; antidepressants; seasonal affective disorder; Alzheimer's disease and much more!
10/29/2003EP1356278A2 Methods and compositions for the identification and treatment of neurodegenerative disorders
10/29/2003EP1355888A1 Quinazolinone derivatives
10/29/2003EP1355639A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/29/2003EP1355588A2 Delivery of therapeutic capable agents
10/29/2003EP1175453B1 Differentially acting op detoxifying sponges
10/29/2003EP1169316B9 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
10/29/2003EP0546118B1 Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
10/29/2003CN1452490A Composition and method for intervening neuronal death using sulfasalazine
10/28/2003US6638913 Concentrated injection and infusion solution for intravenous administration
10/28/2003US6638500 Polyol-IFN-βconjugates modified at Cys-17 and composition containing same
10/28/2003US6638495 Stabilized preparation for use in metered dose inhalers
10/23/2003WO2003087364A1 Novel g protein-coupled receptor and its gene
10/23/2003WO2003087074A1 Phenol compound, process for producing the same, and intermediate therefor
10/23/2003WO2003086459A1 Methods of treatement using ctla-4 antibodies
10/23/2003WO2003029410A3 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
10/23/2003WO2001000812A8 22012, a novel human carboxypeptidase
10/23/2003US20030199701 Treating under hydrolyzing conditions a hydantoin compound to form an alpha-amino acid derivative
10/23/2003US20030199548 Administering quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives containing one of the ring selected from benzene, pyridine, thienyl, furanyl, imidazolyl and triazolyl for therapy in pain management
10/23/2003US20030199502 Indoloquinazolinones
10/23/2003US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated
10/23/2003CA2481207A1 Methods of treatment using ctla-4 antibodies
10/22/2003EP1354878A2 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
10/22/2003EP1354603A1 Concomitant drugs
10/22/2003EP1353906A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/22/2003EP1353692A2 Methods and compositions for treatment of ocular neovascularization and neural injury
10/22/2003EP1353691A2 Molecular antigen array presenting amyloid beta
10/22/2003EP1104446B1 Biologically active fraction of vegetable melanin, process for its production and its use
10/22/2003CN1450905A Method for improving the cell protection
10/22/2003CN1450066A Porphyrin derivate with macrosubstituent, preparation process thereof and use as small molecule antioxidant
10/22/2003CN1449792A Medicine composition with synergrstic action and preparation process and use thereof
10/21/2003US6635288 Pulverizing in solvent; therapy for liver disorders
10/21/2003US6635273 Methods of treating vascular diseases characterized by nitric oxide insufficiency
10/21/2003CA2273989C New histidine derivatives, preparation process, and their use as free antiradical agents
10/21/2003CA2153979C Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
10/16/2003WO2003084940A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084557A1 Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family
10/16/2003WO2003084531A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
10/16/2003WO2003084523A1 Use of a n,n'-dibenzyl-thiourea as medicine
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003022218A3 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
10/16/2003WO2002100347A3 Prodrugs of gaba analogs, compositions and uses thereof
10/16/2003US20030195169 Such as (S)-phosphoric acid mono-(3-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxso-6-trifluoromethyl-2,3 -dihydro-indol-1-ylmethyl)ester; for modulation of large-conductance calcium-activated potassium (BK) channels
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003CA2482253A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/15/2003EP1352640A1 Compositions for retarding skin aging
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
1 ... 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 ... 191